These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 8081414)
61. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Daly AK; Fairbrother KS; Andreassen OA; London SJ; Idle JR; Steen VM Pharmacogenetics; 1996 Aug; 6(4):319-28. PubMed ID: 8873218 [TBL] [Abstract][Full Text] [Related]
62. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Kimura S; Umeno M; Skoda RC; Meyer UA; Gonzalez FJ Am J Hum Genet; 1989 Dec; 45(6):889-904. PubMed ID: 2574001 [TBL] [Abstract][Full Text] [Related]
63. [Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese]. Yokoi T; Kamataki T Nihon Yakurigaku Zasshi; 1998 Jul; 112(1):5-14. PubMed ID: 9755457 [TBL] [Abstract][Full Text] [Related]
64. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Tyndale R; Aoyama T; Broly F; Matsunaga T; Inaba T; Kalow W; Gelboin HV; Meyer UA; Gonzalez FJ Pharmacogenetics; 1991 Oct; 1(1):26-32. PubMed ID: 1844820 [TBL] [Abstract][Full Text] [Related]
65. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309 [TBL] [Abstract][Full Text] [Related]
66. DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers. Mura C; Panserat S; Vincent-Viry M; Galteau MM; Jacqz-Aigrain E; Krishnamoorthy R Hum Genet; 1993 Oct; 92(4):367-72. PubMed ID: 7901140 [TBL] [Abstract][Full Text] [Related]
68. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. Evans WE; Relling MV; Rahman A; McLeod HL; Scott EP; Lin JS J Clin Invest; 1993 May; 91(5):2150-4. PubMed ID: 8098046 [TBL] [Abstract][Full Text] [Related]
69. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Armstrong M; Daly AK; Cholerton S; Bateman DN; Idle JR Lancet; 1992 Apr; 339(8800):1017-8. PubMed ID: 1349052 [TBL] [Abstract][Full Text] [Related]
70. Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in aborigines from western Australia. Griese EU; Ilett KF; Kitteringham NR; Eichelbaum M; Powell H; Spargo RM; LeSouef PN; Musk AW; Minchin RF Pharmacogenetics; 2001 Feb; 11(1):69-76. PubMed ID: 11207032 [TBL] [Abstract][Full Text] [Related]
71. Molecular heterogeneity of the XbaI defined 44kb allele of the CYP2D locus within the Caucasian population. Mura C; Gerard N; Vincent-Viry M; Galteau MM; Jacqz-Aigrain E; Krishnamoorthy R Br J Clin Pharmacol; 1993 Feb; 35(2):161-5. PubMed ID: 8095148 [TBL] [Abstract][Full Text] [Related]
72. Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer. Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Sorsa M; Vainio H Pharmacogenetics; 1992 Dec; 2(6):259-63. PubMed ID: 1306126 [TBL] [Abstract][Full Text] [Related]
73. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity. Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590 [TBL] [Abstract][Full Text] [Related]
74. The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population. Liou YH; Lin CT; Wu YJ; Wu LS J Hum Genet; 2006; 51(10):857. PubMed ID: 16924387 [TBL] [Abstract][Full Text] [Related]
76. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Marez D; Legrand M; Sabbagh N; Lo Guidice JM; Spire C; Lafitte JJ; Meyer UA; Broly F Pharmacogenetics; 1997 Jun; 7(3):193-202. PubMed ID: 9241659 [TBL] [Abstract][Full Text] [Related]
77. The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease. Saitoh T; Xia Y; Chen X; Masliah E; Galasko D; Shults C; Thal LJ; Hansen LA; Katzman R Ann Neurol; 1995 Jan; 37(1):110-2. PubMed ID: 7818242 [TBL] [Abstract][Full Text] [Related]
78. Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls. Tefre T; Daly AK; Armstrong M; Leathart JB; Idle JR; Brøgger A; Børresen AL Pharmacogenetics; 1994 Apr; 4(2):47-57. PubMed ID: 8081413 [TBL] [Abstract][Full Text] [Related]
79. A polymorphic CfoI site in exon 6 of the human cytochrome P450 CYP2D6 gene detected by the polymerase chain reaction. Armstrong M; Idle JR; Daly AK Hum Genet; 1993 Jul; 91(6):616-7. PubMed ID: 8340116 [TBL] [Abstract][Full Text] [Related]
80. An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine. Marez D; Legrand M; Sabbagh N; Lo-Guidice JM; Boone P; Broly F Hum Genet; 1996 May; 97(5):668-70. PubMed ID: 8655150 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]